References
- Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol 2002; 81: 233–243
- Boucher H W, Groll A H, Chiou C C, Walsh T J. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64: 1997–2020
- Martino R. Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature. Curr Med Res Opin 2004; 20: 485–504
- Subira M, Martino R, Gomez L, Marti J M, Estany C, Sierra J. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies – a randomized, controlled trial. Eur J Haematol 2004; 72: 342–347
- Martino R, Subira M, Sureda A, Sierra J. Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies. J Antimicrob Chemother 1999; 44: 569–572
- Ascioglu S, Rex J H, de Pauw B, Bennett J E, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14
- Herbrecht R, Denning D W, Patterson T F, Bennett J E, Greene R E, Oestmann J W, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
- Mora-Duarte J, Betts R, Rotstein C, Colombo A L, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020–2029
- Fleming T R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143–151
- Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemoth 2002; 49(Suppl 1)31–36
- Walsh T J, Goodman J L, Pappas P, Bekersky I, Buell D N, Roden M, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487–496
- Ellis M, Spence D, de Pauw B, Meunier F, Marinus A, Collette L, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27: 1406–1512
- Walsh T J, Hiemenz J W, Seibel N L, Perfect J R, Horwith G, Lee L, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383–1396
- Linden P, Lee L, Walsh T J. Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections. Pharmacotherapy 1999; 19: 1261–1268
- Wingard J R, White M H, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31: 1155–1163
- Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 h: randomised controlled trial. Br Med J 2001; 322: 579–582
- Ioannidis J P, Haidich A B, Pappa M, Pantazis N, Kokori S I, Tektonidou M G, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. J Am Med Assoc 2001; 286: 821–830
- Kontoyiannis D P, Lewis R E. Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 2004; 126: 165–175
- Martino R, Chopra R, Dupont B, et al. Phase I study of combination antifungal therapy with ABLC and caspofungin for empirical therapy of fungal infections in patients with hematological malignancy. Abstract of the 30th Meeting of the EBMT, Barcelona, Spain, 2004. Bone Marrow Transplant 2004; 38(Suppl 1)356